These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 21232658

  • 1. Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance.
    Kristinsson SY, Björkholm M, Schulman S, Landgren O.
    Semin Hematol; 2011 Jan; 48(1):46-54. PubMed ID: 21232658
    [Abstract] [Full Text] [Related]

  • 2. The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease.
    Cohen AL, Sarid R.
    Thromb Res; 2010 Mar; 125(3):216-9. PubMed ID: 19193398
    [Abstract] [Full Text] [Related]

  • 3. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
    Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L.
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
    [Abstract] [Full Text] [Related]

  • 4. Plasma Thrombin Generation and Sensitivity to Activated Protein C Among Patients With Myeloma and Monoclonal Gammopathy of Undetermined Significance.
    Crowley MP, Kevane B, O'Shea SI, Quinn S, Egan K, Gilligan OM, Ní Áinle F.
    Clin Appl Thromb Hemost; 2016 Sep; 22(6):554-62. PubMed ID: 26759370
    [Abstract] [Full Text] [Related]

  • 5. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
    Za T, De Stefano V, Rossi E, Petrucci MT, Andriani A, Annino L, Cimino G, Caravita T, Pisani F, Ciminello A, Torelli F, Villivà N, Bongarzoni V, Rago A, Betti S, Levi A, Felici S, Gentilini F, Calabrese E, Leone G, Multiple Myeloma GIMEMA-Latium Region Working Group.
    Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
    [Abstract] [Full Text] [Related]

  • 6. Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance.
    O'Sullivan LR, Meade-Murphy G, Gilligan OM, Mykytiv V, Young PW, Cahill MR.
    Br J Haematol; 2021 Jan; 192(2):322-332. PubMed ID: 32478420
    [Abstract] [Full Text] [Related]

  • 7. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
    Dezube BJ, Aboulafia DM, Pantanowitz L.
    AIDS Read; 2004 Jul; 14(7):372-4, 377-9. PubMed ID: 15282866
    [Abstract] [Full Text] [Related]

  • 8. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N, Voorhees PM, Mackman N, Key NS.
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [Abstract] [Full Text] [Related]

  • 9. Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance.
    Muslimani AA, Spiro TP, Chaudhry AA, Taylor HC, Jaiyesimi I, Daw HA.
    Clin Adv Hematol Oncol; 2009 Dec; 7(12):827-32. PubMed ID: 20332755
    [Abstract] [Full Text] [Related]

  • 10. [50-year-old man with fatigue and monoclonal gammopaty].
    Raeder H, Kildahl-Andersen O, Stalsberg H.
    Tidsskr Nor Laegeforen; 2007 Oct 18; 127(20):2677-9. PubMed ID: 17972388
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
    Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA.
    Cancer; 2004 Aug 01; 101(3):558-66. PubMed ID: 15274069
    [Abstract] [Full Text] [Related]

  • 12. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group.
    Leukemia; 2008 Feb 01; 22(2):414-23. PubMed ID: 18094721
    [Abstract] [Full Text] [Related]

  • 13. Multiple myeloma and its treatment contribute to increased platelet reactivity.
    Mitchell JL, Khan D, Rana RH, Kriek N, Unsworth AJ, Sage T, Bye AP, Laffan M, Shapiro S, Thakurta A, Grech H, Ramasamy K, Gibbins JM.
    Platelets; 2023 Dec 01; 34(1):2264940. PubMed ID: 37822056
    [Abstract] [Full Text] [Related]

  • 14. Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
    Jimenez-Zepeda VH, Heilman RL, Engel RA, Carey EJ, Freeman C, Rakela J, Mulligan DC, Fonseca R, Stewart AK.
    Transplantation; 2011 Sep 15; 92(5):570-4. PubMed ID: 21712755
    [Abstract] [Full Text] [Related]

  • 15. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression.
    Kyle RA, Rajkumar SV.
    Br J Haematol; 2007 Dec 15; 139(5):730-43. PubMed ID: 18021088
    [Abstract] [Full Text] [Related]

  • 16. [Monoclonal gammopathy of undetermined significance--potential risk factor of multiple myeloma].
    Stelmach-Gołdyś A, Czarkowska-Paczek B.
    Przegl Lek; 2012 Dec 15; 69(5):194-6. PubMed ID: 23050415
    [Abstract] [Full Text] [Related]

  • 17. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA.
    Ann Hematol; 2002 Jul 15; 81(7):357-61. PubMed ID: 12185503
    [Abstract] [Full Text] [Related]

  • 18. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U, Kosely F, Hillengass J, Hundemer M, Schmitt S, Neben K, Moehler T, Hegenbart U, Ho AD, Goldschmidt H.
    Ann Hematol; 2009 Jan 15; 88(1):67-71. PubMed ID: 18668241
    [Abstract] [Full Text] [Related]

  • 19. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M.
    Semin Thromb Hemost; 2011 Apr 15; 37(3):209-19. PubMed ID: 21455855
    [Abstract] [Full Text] [Related]

  • 20. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A, Ortuño FJ, Osma Mdel M, Español I, González AD, Roldán V, de Arriba F, Vicente V.
    Ann Med; 2009 Apr 15; 41(7):547-58. PubMed ID: 19634064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.